GAITHERSBURG, Md., Aug. 1, 2023
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global
company advancing protein-based vaccines with its novel
Matrix-M™ adjuvant, today announced it will report its second
quarter 2023 financial results and operational highlights at
8:30 a.m. Eastern Daylight Time (EDT)
on Tuesday, August 8, 2023. Details
of the event and replay are as follows:
Conference call
details:
|
|
Date:
|
August 8,
2023
|
Time:
|
8:30 a.m. U.S.
EDT
|
Dial-in number:
|
(877) 883-0383
(Domestic) or (412) 902-6506 (International)
|
Passcode:
|
1209328
|
Webcast:
|
ir.novavax.com/events
|
- Participants will be prompted to request to join the
Novavax, Inc. call.
- To ensure a timely connection, it is recommended that
participants join at least 10 minutes prior to the scheduled
webcast.
Replay
details:
|
|
Date:
|
Available starting at
11:30 a.m. EDT, August 8, 2023, until 11:59 p.m. U.S. EDT, August
15, 2023
|
Dial-in number:
|
(877) 344-7529
(Domestic) or (412) 317-0088 (International)
|
Passcode:
|
2287018
|
Webcast:
|
ir.novavax.com/events,
until November 6, 2023
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to protect against serious infectious diseases.
Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID, influenza, and COVID and influenza
combined. Please visit novavax.com and LinkedIn for more
information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-2023-financial-results-and-operational-highlights-on-august-8-2023-301890257.html
SOURCE Novavax, Inc.